Circulating sphingolipids in relation to cognitive decline and incident dementia: The Cardiovascular Health Study.

ABSTRACT:

Introduction

Whether circulating levels of sphingolipids are prospectively associated with cognitive decline and dementia risk is uncertain.

Methods

We measured 14 sphingolipid species in plasma samples from 4488 participants (mean age 76.2 years; 40% male; and 25% apolipoprotein E (APOE) ε4 allele carriers). Cognitive decline was assessed annually across 6 years using modified Mini-Mental State Examination (3MSE) and Digital Symbol Substitution Test (DSST). Additionally, a subset of 3050 participants were followed for clinically adjudicated dementia.

Results

Higher plasma levels of sphingomyelin-d18:1/16:0 (SM-16) were associated with a faster cognitive decline measured with 3MSE, in contrast, higher levels of sphingomyelin-d18:1/22:0 (SM-22) were associated w

SUBMITTER: Moseholm KF 

PROVIDER: S-EPMC11310412 | biostudies-literature | 2024 Jul-Sep

REPOSITORIES: biostudies-literature